DGIdb - METHAMPHETAMINE Drug Record

METHAMPHETAMINE chembl:CHEMBL1201201

Alternate Names:

METHAMPHETAMINE
METAMFETAMINE
J6.362B
NSC-25115
D-N-METHYLAMPHETAMINE
METANFETAMINA
MÉTAMFÉTAMINE
DESOXYEPHEDRINE
(S)-N,ALPHA-DIMETHYLBENZENEETHANAMINE
D-DEOXYEPHEDRINE
(ALPHAS)-N,ALPHA-DIMETHYLBENZENEETHANAMINE
(ΑS)-N,Α-DIMETHYLBENZENEETHANAMINE
METHAMPHETAMINE, METHYLAMPHETAMINE
(+)-(S)-P-Α-DIMETHYLPHENETHYLAMINE
D-DESOXYEPHEDRINE
METHYL-Β-PHENYLISOPROPYLAMINE
N-METHYLAMPHETAMINE
D-PHENYLISOPROPYLMETHYLAMINE
METHYL-BETA-PHENYLISOPROPYLAMINE
METAMFETAMINUM
(+)-(S)-N-ALPHA-DIMETHYLPHENETHYLAMINE
METHAMPHETAMINUM
S-METHAMPHETAMINE
METH
D-1-PHENYL-2-METHYLAMINOPROPANE
(S)-N,Α-DIMETHYLBENZENEETHANAMINE
METHYLAMPHETAMINE
DEXTROMETHAMPHETAMINE
chemidplus:537-46-2
pubchem.compound:10836
chembl:CHEMBL1201201
rxcui:6816
drugbank:01577

Drug Info:

Year of Approval	approved before 1982
Drug Class	central nervous system stimulants
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	neuroprotectant

(1 More Sources)

Publications:

Gupta S et al., 2011, Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings., J Neurovirol
Ulus et al., 2000, Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors., Biochem. Pharmacol.
Sulzer et al., 2005, Mechanisms of neurotransmitter release by amphetamines: a review., Prog. Neurobiol.
Kishimoto M et al., 2008, The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis., Biol Psychiatry
Borowsky et al., 2001, Trace amines: identification of a family of mammalian G protein-coupled receptors., Proc. Natl. Acad. Sci. U.S.A.
Grandy, 2007, Trace amine-associated receptor 1-Family archetype or iconoclast?, Pharmacol. Ther.
Wolinsky et al., 2007, The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia., Genes Brain Behav.
Xie et al., 2007, Trace amine-associated receptor 1 is a modulator of the dopamine transporter., J. Pharmacol. Exp. Ther.
Miller et al., 2005, Primate trace amine receptor 1 modulation by the dopamine transporter., J. Pharmacol. Exp. Ther.
Xie et al., 2007, Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro., J. Pharmacol. Exp. Ther.
Reese et al., 2007, Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine., J. Pharmacol. Exp. Ther.
Horton et al., 2011, meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release., J. Pharmacol. Exp. Ther.
Yasumoto et al., 2009, Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2., Neurosci. Lett.
Fleckenstein et al., 2007, New insights into the mechanism of action of amphetamines., Annu. Rev. Pharmacol. Toxicol.
Sulzer et al., 1995, Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport., J. Neurosci.
Chanasong R et al., 2013, Genetic variation of GRIN1 confers vulnerability to methamphetamine-dependent psychosis in a Thai population., Neurosci Lett
Jeng et al., 1998, Methamphetamine modulates GABA-induced electrophysiological depression by alternating noradrenergic actions in cerebellar Purkinje neurons., Psychopharmacology (Berl.)
Nishio et al., 2002, Methamphetamine increases the hippocampal alpha(2A)-adrenergic receptor and Galpha(o) in mice., Neurosci. Lett.
Numachi et al., 2007, Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters., Eur. J. Pharmacol.
Sora et al., 2009, Monoamine transporter as a target molecule for psychostimulants., Int. Rev. Neurobiol.
Tellez et al., 2010, Autoradiographic study of serotonin transporter during memory formation., Behav. Brain Res.
Henry et al., 1998, The vesicular monoamine transporter: from chromaffin granule to brain., Neurochem. Int.
Garcia et al., 2005, Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution., Mol. Pharmacol.
Escubedo et al., 2009, Involvement of nicotinic receptors in methamphetamine- and MDMA-induced neurotoxicity: pharmacological implications., Int. Rev. Neurobiol.
Fone et al., 2005, Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder., Curr Opin Pharmacol
Lott et al., 2005, Dopamine transporter gene associated with diminished subjective response to amphetamine., Neuropsychopharmacology
Madras et al., 2005, The dopamine transporter and attention-deficit/hyperactivity disorder., Biol. Psychiatry
Kahlig et al., 2005, Amphetamine induces dopamine efflux through a dopamine transporter channel., Proc. Natl. Acad. Sci. U.S.A.
Gao X et al., 2017, Contribution of Genetic Polymorphisms and Haplotypes in DRD2, BDNF, and Opioid Receptors to Heroin Dependence and Endophenotypes Among the Han Chinese., OMICS
Iamjan SA et al., 2015, BDNF (Val66Met) genetic polymorphism is associated with vulnerability for methamphetamine dependence., Pharmacogenomics
Haerian BS, 2013, BDNF rs6265 polymorphism and drug addiction: a systematic review and meta-analysis., Pharmacogenomics
Matsuzawa D et al., 2007, Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis., Am J Psychiatry
Kishi T et al., 2010, Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients., Neuropharmacology
Kotaka T et al., 2009, G72 gene is associated with susceptibility to methamphetamine psychosis., Prog Neuropsychopharmacol Biol Psychiatry
Kishi T et al., 2009, A functional polymorphism in estrogen receptor alpha gene is associated with Japanese methamphetamine induced psychosis., Prog Neuropsychopharmacol Biol Psychiatry
Ide S et al., 2006, Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms., Pharmacogenomics J
Zhang W et al., 2020, FAAH levels and its genetic polymorphism association with susceptibility to methamphetamine dependence., Ann Hum Genet
Sim MS et al., 2013, Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population., Pharmacogenomics
Ikeda M et al., 2007, Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia., Genes Brain Behav
Sun Y et al., 2019, Identification of novel risk loci with shared effects on alcoholism, heroin, and methamphetamine dependence., Mol Psychiatry

METHAMPHETAMINE SLC18A1

Interaction Score: 9.51

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
9587917 15955613 17209801

Sources:
TdgClinicalTrial
METHAMPHETAMINE DAOA

Interaction Score: 4.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19482054

Sources:
PharmGKB
METHAMPHETAMINE PICK1

Interaction Score: 4.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17606663

Sources:
PharmGKB
METHAMPHETAMINE ANKS1B

Interaction Score: 1.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31462767

Sources:
PharmGKB
METHAMPHETAMINE ARRB2

Interaction Score: 1.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17233643

Sources:
PharmGKB
METHAMPHETAMINE DTNBP1

Interaction Score: 1.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17555717

Sources:
PharmGKB
METHAMPHETAMINE SLC18A2

Interaction Score: 0.75

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
21177475 19429089 17209801 15955613 7751968

Sources:
TdgClinicalTrial
METHAMPHETAMINE TAAR1

Interaction Score: 0.68

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Novel drug target Established target

Trial Name low dose intravenous methamphetamine

PMIDs:
11459929 17888514 17212650 17234899 15764732 17234900 17218486

Sources:
TdgClinicalTrial
METHAMPHETAMINE SLC6A3

Interaction Score: 0.42

Interaction Types & Directionality:

negative modulator (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
15795321 19897077 15661631 15602501 15950014 15764732 17209801 15728379

Sources:
TdgClinicalTrial
METHAMPHETAMINE FAAH

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31789429 23556448

Sources:
PharmGKB
METHAMPHETAMINE MAOA

Interaction Score: 0.27

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
10799660 15955613

Sources:
TdgClinicalTrial
METHAMPHETAMINE SLC6A2

Interaction Score: 0.18

Interaction Types & Directionality:

negative modulator (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
15955613 17209801

Sources:
TdgClinicalTrial
METHAMPHETAMINE SLC6A4

Interaction Score: 0.18

Interaction Types & Directionality:

negative modulator (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
17673199 19607959 20226815

Sources:
TdgClinicalTrial
METHAMPHETAMINE MAOB

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name low dose intravenous methamphetamine

PMIDs:
10799660 15955613

Sources:
TdgClinicalTrial
METHAMPHETAMINE BDNF

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28692418 26401760 24279859

Sources:
PharmGKB
METHAMPHETAMINE ADRA2B

Interaction Score: 0.15

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
9551769 15955613

Sources:
TdgClinicalTrial
METHAMPHETAMINE ADRA2A

Interaction Score: 0.13

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
9551769 12453616 15955613

Sources:
TdgClinicalTrial
METHAMPHETAMINE GRIN1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23880023

Sources:
PharmGKB
METHAMPHETAMINE ADRA2C

Interaction Score: 0.12

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
9551769 15955613

Sources:
TdgClinicalTrial
METHAMPHETAMINE HTR1A

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19747927

Sources:
PharmGKB
METHAMPHETAMINE ADRA1B

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TEND TTD
METHAMPHETAMINE DRD3

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21491142

Sources:
PharmGKB
METHAMPHETAMINE OPRM1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16402083

Sources:
PharmGKB
METHAMPHETAMINE ADRA1A

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TEND
METHAMPHETAMINE ESR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19386276

Sources:
PharmGKB
METHAMPHETAMINE DRD2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD

TEND: METHAMPHETAMINE
- Version: 01-August-2011
Alternate Names:

METHAMPHETAMINE Primary Drug Name

Drug Info:

Drug Class central nervous system stimulants

Year of Approval approved before 1982

Publications:
TdgClinicalTrial: METHAMPHETAMINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications neuroprotectant

Drug Class Small Molecule

FDA Approval approved

Publications:

PharmGKB: methamphetamine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Gupta S et al., 2011, Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings., J Neurovirol

Kishimoto M et al., 2008, The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis., Biol Psychiatry

Matsuzawa D et al., 2007, Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis., Am J Psychiatry

TTD: Methamphetamine
- Version: 2020.06.01
Alternate Names:

D0P6UB TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201201
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	low dose intravenous methamphetamine
Novel drug target	Established target

METHAMPHETAMINE Drug Record

METHAMPHETAMINE chembl:CHEMBL1201201

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name low dose intravenous methamphetamine Novel drug target Established target

PMIDs: 9587917 15955613 17209801

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19482054

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17606663

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31462767

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17233643

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17555717

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name low dose intravenous methamphetamine Novel drug target Established target

PMIDs: 21177475 19429089 17209801 15955613 7751968

Sources: TdgClinicalTrial

Interaction Types & Directionality: agonist (activating)

Interaction Info: Novel drug target Established target Trial Name low dose intravenous methamphetamine

PMIDs: 11459929 17888514 17212650 17234899 15764732 17234900 17218486

Sources: TdgClinicalTrial

Interaction Types & Directionality: negative modulator (inhibitory)

Interaction Info: Trial Name low dose intravenous methamphetamine Novel drug target Established target

PMIDs: 15795321 19897077 15661631 15602501 15950014 15764732 17209801 15728379

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31789429 23556448

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name low dose intravenous methamphetamine Novel drug target Established target

PMIDs: 10799660 15955613

Sources: TdgClinicalTrial

Interaction Types & Directionality: negative modulator (inhibitory)

Interaction Info: Trial Name low dose intravenous methamphetamine Novel drug target Established target

PMIDs: 15955613 17209801

Sources: TdgClinicalTrial

Interaction Types & Directionality: negative modulator (inhibitory)

Interaction Info: Trial Name low dose intravenous methamphetamine Novel drug target Established target

PMIDs: 17673199 19607959 20226815

Sources: TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name low dose intravenous methamphetamine

PMIDs: 10799660 15955613

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28692418 26401760 24279859

Sources: PharmGKB

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name low dose intravenous methamphetamine Novel drug target Established target

PMIDs: 9551769 15955613

Sources: TdgClinicalTrial

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name low dose intravenous methamphetamine Novel drug target Established target

PMIDs: 9551769 12453616 15955613

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23880023

Sources: PharmGKB

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name low dose intravenous methamphetamine Novel drug target Established target

PMIDs: 9551769 15955613

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
9587917 15955613 17209801

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
19482054

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17606663

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31462767

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17233643

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17555717

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
21177475 19429089 17209801 15955613 7751968

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Novel drug target Established target

Trial Name low dose intravenous methamphetamine

PMIDs:
11459929 17888514 17212650 17234899 15764732 17234900 17218486

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

negative modulator (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
15795321 19897077 15661631 15602501 15950014 15764732 17209801 15728379

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
31789429 23556448

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
10799660 15955613

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

negative modulator (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
15955613 17209801

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

negative modulator (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
17673199 19607959 20226815

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name low dose intravenous methamphetamine

PMIDs:
10799660 15955613

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
28692418 26401760 24279859

Sources:
PharmGKB

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
9551769 15955613

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
9551769 12453616 15955613

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
23880023

Sources:
PharmGKB

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
9551769 15955613

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
19747927

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
21491142

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16402083

Sources:
PharmGKB